Skip to content

Clinical trials

Ciliary Motility Disorders trials in the United States

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Ciliary Motility Disorders Country / region: United States Clear all

28 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20001
20041
20063
20082
20091
20151
20162
20171
20192
20201
20214
20221
20235
20242
20261

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed16
Recruiting7
Active, not recruiting2
Not yet recruiting1
Terminated1
Unknown status1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
University of North Carolina, Chapel Hill10
ReCode Therapeutics4
Indiana University2
National Heart, Lung, and Blood Institute (NHLBI)2
Vanderbilt University Medical Center2
Arkansas Children's Hospital Research Institute1
Connecticut Children's Medical Center1
Johns Hopkins University1
National Center for Research Resources (NCRR)1
National Institute of Allergy and Infectious Diseases (NIAID)1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Ciliary Motility Disorders28
Kartagener Syndrome12
Cystic Fibrosis5
Autoimmune Diseases2
Bronchiectasis2
Primary Immunodeficiency Diseases2
Pseudohypoaldosteronism2
Pulmonary Disease, Chronic Obstructive2
Asthma1
Bronchial Hyperreactivity1

Trials

Showing 1 to 25 of 28. Each trial links to its page on Pharma Observatory.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.